Medivation (MDVN) was upgraded to buy at Citigroup. $73 price target. Xtandi also now appears to be effective against breast cancer, Citigroup said.
Occidental Petroleum (OXY - Get Report) was downgraded to neutral from overweight at JPMorgan. The company was also removed from the Analyst Focus list. The valuation is less attractive, based on an $80 price target, JPMorgan said.